Board Stats

Bristol-Myers Squibb Co.

Please accept my sincerest apologies for failing to publicly acknowledge our fallen heroes this past Memorial Day. No excuse I could offer could justify the oversight. Along with you, I salute the many men and women who have proudly and selflessly served in our military to protect, defend and secure the freedoms and liberties we enjoy each and every day. Their bravery in making the ultimate sacrifice will forever be appreciated and they will always be remembered and celebrated and never taken for granted or forgotten.

BMY / Message Board / Read Message

BOARD

GROUPS

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

Msg 11002 of 11272 at 3/30/2023 4:44:33 PM by

Send PM

16:29 EDT

BMY

		Juno Therapeutics' lisocabtagene maraleucel receives FDA orphan designation
		According to a post on the FDA's website, Juno Therapeutics, a Bristol-Myers Squibb company, received orphan designation for its treatment of nodal marginal zone lymphoma, lisocabtagene maraleucel.

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=933723

Generic Name:	lisocabtagene maraleucel
Date Designated:	03/30/2023
Orphan Designation:	Treatment of nodal marginal zone lymphoma
Orphan Designation Status:	Designated
FDA Orphan Approval Status:	Not FDA Approved for Orphan Indication
Sponsor:	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 400 Dexter Avenue N. Suite 1200 Seattle, Washington 98109 United States The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.

add to library

Recs: 7

BOARDS Sign In for Filters